高龄对接受化疗的晚期卵巢癌女性治疗结局的影响:NRG-Oncology/妇科肿瘤组(GOG-0182-ICON5)辅助研究
该辅助研究纳入2001至2004年间GOG 0182-ICON5中III或IV期上皮性卵巢癌术后化疗患者3686例,按年龄<70岁与≥70岁分组比较。≥70岁患者总生存37.2个月,低于<70岁患者的45.0个月(HR 1.21,95%CI 1.09-1.34,p<0.001);在卡铂/紫杉醇组,≥70岁患者完成治疗的可能性与年轻患者相当,但≥2级周围神经病变发生率更高(35.7% vs 19.7%,p<0.001)。
要点
- ≥70岁晚期上皮性卵巢癌患者总生存37.2个月,低于<70岁患者的45.0个月(HR 1.21,95%CI 1.09-1.34,p<0.001)。
- ≥70岁患者癌症特异性死亡风险升高(HR 1.16,95%CI 1.04-1.29),非癌症相关死亡风险亦升高(HR 2.78,95%CI 2.00-3.87)。
- 卡铂/紫杉醇组中≥70岁患者完成治疗的可能性与年轻患者相当,但≥2级周围神经病变发生率更高(35.7% vs 19.7%,p<0.001)。
核心结论
- 在接受化疗的晚期上皮性卵巢癌女性中,年龄≥70岁与较短的总生存和癌症特异性生存相关。
- 接受卡铂和紫杉醇的≥70岁患者≥2级神经病变报告率更高,但其他化疗相关毒性未见更易发生。
研究设计与样本
- NRG-Oncology/妇科肿瘤组(GOG-0182-ICON5)辅助研究,纳入2001至2004年间入组GOG 0182-ICON5、接受手术和化疗的III或IV期上皮性卵巢癌女性。
- 共纳入3686例患者,其中620例(16.8%)≥70岁;患者按年龄<70岁与≥70岁分组,比较基线特征、治疗依从性、毒性和临床结局。
主要发现
- ≥70岁患者总生存37.2个月,<70岁患者45.0个月(HR 1.21,95%CI 1.09-1.34,p<0.001)。
- ≥70岁患者癌症特异性死亡风险升高(HR 1.16,95%CI 1.04-1.29),非癌症相关死亡风险亦升高(HR 2.78,95%CI 2.00-3.87)。
- ≥70岁患者中位无进展生存15.1个月,<70岁患者16.0个月(HR 1.10,95%CI 1.00-1.20,p=0.056)。
- 在卡铂/紫杉醇组,≥70岁患者完成治疗的可能性与年轻患者相当,≥2级周围神经病变发生率更高(35.7% vs 19.7%,p<0.001)。
- 两组间其他毒性风险保持相等。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To assess the effect of age on overall survival (OS) in women with ovarian cancer receiving chemotherapy. Secondary objectives were to describe the effect of age on treatment compliance, toxicities, progression free survival (PFS), time from surgery to chemotherapy, and rates of optimal cytoreduction. METHODS: Women enrolled in GOG 0182-ICON5 with stage III or IV epithelial ovarian cancer (EOC) who underwent surgery and chemotherapy between 2001 and 2004 were included. Patients were divided into ages <70 and ≥ 70 years. Baseline characteristics, treatment compliance, toxicities, and clinical outcomes were compared. RESULTS: We included a total of 3686 patients, with 620 patients (16.8%) ≥ 70 years. OS was 37.2 months in older compared to 45.0 months in younger patients (HR 1.21, 95% CI, 1.09-1.34, p < 0.001). Older patients had an increased risk of cancer-specific-death (HR 1.16, 95% CI, 1.04-1.29) as well as non-cancer related deaths (HR 2.78, 95% CI, 2.00-3.87). Median PFS was 15.1 months in older compared to 16.0 months in younger patients (HR 1.10, 95% CI, 1.00-1.20, p = 0.056). In the carboplatin/paclitaxel arm, older patients were just as likely to complete therapy and more likely to develop grade ≥ 2 peripheral neuropathy (35.7 vs 19.7%, p < 0.001). Risk of other toxicities remained equal between groups. CONCLUSIONS: In women with advanced EOC receiving chemotherapy, age ≥ 70 was associated with shorter OS and cancer specific survival. Older patients receiving carboplatin and paclitaxel reported higher rates of grade ≥ 2 neuropathy but were not more likely to suffer from other chemotherapy related toxicities. Clintrials.gov: NCT00011986.
引用
- Sia TY, Tew WP, Purdy C, et al. The effect of older age on treatment outcomes in women with advanced ovarian cancer receiving chemotherapy: An NRG-Oncology/Gynecologic Oncology Group (GOG-0182-ICON5) ancillary study. Gynecol Oncol. 2023. PMID: 37148580. doi:10.1016/j.ygyno.2023.03.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。